An Unusual Case of Metastatic Basal Cell Carcinoma of the Prostate: A Case Report and Literature Review

被引:10
作者
Dong, Shiqiang [1 ]
Liu, Qing [1 ]
Xu, Zihan [1 ]
Wang, Haitao [1 ]
机构
[1] Tianjin Med Univ, Dept Oncol, Hosp 2, Tianjin Inst Urol, Tianjin, Peoples R China
基金
中国国家自然科学基金;
关键词
basal cell carcinoma; prostate; metastasis; case report; therapy; ATM DEFICIENCY; TUMOR; SENSITIVITY;
D O I
10.3389/fonc.2020.00859
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Primary basal cell carcinoma (BCC) is a rare prostate cancer. Currently, a standard treatment regime for BCC of the prostate is lacking and most patients have a poor prognosis. We reported on a patient with BCC of the prostate whose cancer metastasized after undergoing a radical prostatectomy and whose prognosis improved after treatment with etoposide. Case Presentation: A 62-year-old male with a history of seminoma was admitted complaining of intermittent gross hematuria for 1 month. Following a prostate biopsy, the patient was diagnosed with BCC of the prostate and received radical prostatectomy and radiotherapy. Initially, the patient's symptoms improved; however, 2 years later, a chest computed tomography (CT) scan revealed lung nodules. The patient did not exhibit any symptoms of BCC of the prostate; however, pathological examination and immunohistochemical staining of the nodules confirmed metastatic BCC of the prostate. Chemotherapy with docetaxel and cisplatin was well-tolerated but did not slow disease progression. Next-generation sequencing revealed mutations in the ataxia telangiectasia-mutated (ATM), SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily b-member 1 (SMARCB1), and phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) genes. The patient did not receive targeted therapy owing to financial limitations and instead, etoposide was administered. A 9-month follow-up chest CT scan showed an 80% reduction in existing lung nodules and no new nodules had developed. Conclusion: Our patient, diagnosed with recurrent prostate BCC after receiving a radical prostatectomy, responded to treatment with etoposide. Radical prostatectomy and radiotherapy should remain first-line therapy; however, etoposide may be an alternative second-line therapy when other options are not available. Consensus regarding treatment plans, and the molecular mechanisms behind prostate BBC, must be elucidated.
引用
收藏
页数:5
相关论文
共 23 条
[1]   Basal cell carcinoma of the prostate: A clinicopathologic study of 29 cases [J].
Ali, Tehmina Z. ;
Epstein, Jonathan I. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2007, 31 (05) :697-705
[2]   Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells [J].
Alimova, Irina ;
Birks, Diane K. ;
Harris, Peter S. ;
Knipstein, Jeffrey A. ;
Venkataraman, Sujatha ;
Marquez, Victor E. ;
Foreman, Nicholas K. ;
Vibhakar, Rajeev .
NEURO-ONCOLOGY, 2013, 15 (02) :149-160
[3]   Basal cell carcinoma of the prostate: current concepts [J].
Ayyathurai, Rajinikanth ;
Civantos, Francisco ;
Soloway, Mark S. ;
Manoharan, Murugesan .
BJU INTERNATIONAL, 2007, 99 (06) :1345-1349
[4]   A subset of prostatic basal cell carcinomas harbor the MYB rearrangement of adenoid cystic carcinoma [J].
Bishop, Justin A. ;
Yonescu, Raluca ;
Epstein, Jonathan I. ;
Westra, William H. .
HUMAN PATHOLOGY, 2015, 46 (08) :1204-1208
[5]   Basal cell carcinoma of the prostate: clinicopathologic analysis of three cases and a review of the literature [J].
Chang, Kun ;
Dai, Bo ;
Kong, YunYi ;
Qu, YuanYuan ;
Wu, JianNong ;
Ye, DingWei ;
Yao, XuDong ;
Zhang, ShiLin ;
Zhang, HaiLiang ;
Zhu, Yao ;
Yao, WeiQiang .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2013, 11 :1-6
[6]   Insights into the oncogenic effects of PIK3CA mutations from the structure of p110α/p85α [J].
Huang, Chuan-Hsiang ;
Mandelker, Diana ;
Gabelli, Sandra B. ;
Amzel, L. Mario .
CELL CYCLE, 2008, 7 (09) :1151-1156
[7]   Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression [J].
Huang, Xiaoxu ;
Li, Zheng ;
Zhang, Qiang ;
Wang, Weizhi ;
Li, Bowen ;
Wang, Lu ;
Xu, Zhipeng ;
Zeng, Ailiang ;
Zhang, Xing ;
Zhang, Xuan ;
He, Zhongyuan ;
Li, Qiang ;
Sun, Guangli ;
Wang, Sen ;
Li, Qing ;
Wang, Linjun ;
Zhang, Lu ;
Xu, Hao ;
Xu, Zekuan .
MOLECULAR CANCER, 2019, 18 (1)
[8]   Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu [J].
Iczkowski, K. A. ;
Montironi, R. .
JOURNAL OF CLINICAL PATHOLOGY, 2006, 59 (12) :1327-1330
[9]   Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway [J].
Jagani, Zainab ;
Mora-Blanco, E. Lorena ;
Sansam, Courtney G. ;
McKenna, Elizabeth S. ;
Wilson, Boris ;
Chen, Dongshu ;
Klekota, Justin ;
Tamayo, Pablo ;
Nguyen, Phuong T. L. ;
Tolstorukov, Michael ;
Park, Peter J. ;
Cho, Yoon-Jae ;
Hsiao, Kathy ;
Buonamici, Silvia ;
Pomeroy, Scott L. ;
Mesirov, Jill P. ;
Ruffner, Heinz ;
Bouwmeester, Tewis ;
Luchansky, Sarah J. ;
Murtie, Joshua ;
Kelleher, Joseph F. ;
Warmuth, Markus ;
Sellers, William R. ;
Roberts, Charles W. M. ;
Dorsch, Marion .
NATURE MEDICINE, 2010, 16 (12) :1429-U112
[10]   Predictive biomarkers for cancer therapy with PARP inhibitors [J].
Michels, J. ;
Vitale, I. ;
Saparbaev, M. ;
Castedo, M. ;
Kroemer, G. .
ONCOGENE, 2014, 33 (30) :3894-3907